Study guide
10.4 Trop-2 Antibody-Drug Conjugates, PI3K/AKT/mTOR Inhibitors & New Oral SERDs
CBCN Certified Breast Care Nurse Exam
Track your progress as you read
Finished sections get a check mark.
1 Introduction: The CBCN Exam
CBCN Exam Facts, 2026 Blueprint & Study Plan
2 Chapter 1: Breast Health, Examination & Benign Conditions (Care Continuum)
1.1 Breast Anatomy, Vascular Supply & Hormonal Physiology 1.2 Clinical Breast Examination & Breast Awareness Education 1.3 Benign Breast Conditions, Mastalgia & Fibrocystic Changes
3 Chapter 2: Screening, Breast Density & Special Populations (Care Continuum)
2.1 Screening Modalities, Breast Density & Pharmacologic Risk Reduction 2.2 Screening & Breast Health in Special Populations
4 Chapter 3: Cancer Risk Assessment & Genetics (Care Continuum)
3.1 Proliferative Lesions, Atypia & High-Risk Benign Pathology 3.2 Breast Cancer Risk Models (Gail, Tyrer-Cuzick, Claus, BRCAPRO) 3.3 Hereditary Cancer Syndromes & Genetic Evaluation
5 Chapter 4: Patient Navigation, Surveillance & Survivorship (Care Continuum)
4.1 Patient Navigation, Barriers to Care, Social Determinants & Interprofessional Collaboration 4.2 Survivorship Care Planning, Surveillance Intervals & Recurrence Monitoring 4.3 Secondary Prevention, Physical Activity, Nutrition & Wellness Guidance
6 Chapter 5: Carcinogenesis & Diagnostic Evaluation (Diagnosis and Staging)
5.1 Carcinogenesis: How Breast Cancer Develops and Spreads 5.2 Clinical Assessment, Diagnostic Imaging & BI-RADS Categorization 5.3 Breast Biopsy Modalities & Image-Guided Localization Techniques
7 Chapter 6: Pathology, Biomarkers & Genomic Testing (Diagnosis and Staging)
6.1 Histopathology: In Situ Carcinomas & Invasive Carcinoma Subtypes 6.2 Receptor Biomarkers (ER, PR, HER2, Ki-67) & Molecular Subtypes 6.3 Multigene Genomic Assays & Recurrence Risk Stratification
8 Chapter 7: Clinical & Pathologic Staging (Diagnosis and Staging)
7.1 AJCC TNM Staging System (Anatomic vs Prognostic Staging) 7.2 Staging Workup: When to Use MRI, CT, Bone Scan & PET
9 Chapter 8: Breast Surgery, Axillary Staging & Reconstruction (Treatment Modalities)
8.1 Breast-Conserving Surgery, Margin Standards & Mastectomy Techniques 8.2 Axillary Staging: Sentinel Lymph Node Biopsy vs. Axillary Dissection 8.3 Post-Mastectomy Reconstruction & Oncoplastic Surgery
10 Chapter 9: Radiation Therapy & Chemotherapy (Treatment Modalities)
9.1 Radiation Therapy: Whole Breast, Chest Wall, Regional Nodal & Partial Breast Irradiation 9.2 Neoadjuvant vs. Adjuvant Chemotherapy Principles & Standard Regimens
11 Chapter 10: Endocrine, HER2-Targeted & Novel Systemic Therapies (Treatment Modalities)
10.1 Endocrine Therapy: SERMs, Aromatase Inhibitors, Ovarian Suppression & SERDs 10.2 HER2-Targeted Monoclonal Antibodies, Antibody-Drug Conjugates & Kinase Inhibitors 10.3 CDK4/6 Inhibitors, PARP Inhibitors & Immune Checkpoint Blockade 10.4 Trop-2 Antibody-Drug Conjugates, PI3K/AKT/mTOR Inhibitors & New Oral SERDs
12 Chapter 11: Specific Conditions & Special Populations (Treatment Modalities)
11.1 Triple-Negative Breast Cancer: Treatment Considerations 11.2 HER2-Positive Breast Cancer: Treatment Considerations 11.3 Inflammatory Breast Cancer & Paget Disease of the Nipple 11.4 Phyllodes Tumors & Breast Angiosarcoma 11.5 Treatment Considerations for Special Populations
13 Chapter 12: Symptom Management & Supportive Care (Nursing Practice)
12.1 Acute Chemotherapy Toxicities, Supportive Regimens & Oncologic Emergencies 12.2 Lymphedema Pathophysiology, ISL Staging & Complete Decongestive Therapy (CDT) 12.3 Musculoskeletal Toxicities, Bone Health & Vasomotor/GSM Relief 12.4 Complementary & Integrative Modalities 12.5 Cancer Rehabilitation: Physical, Occupational & Pelvic Floor Therapy
14 Chapter 13: Oncologic Emergencies (Nursing Practice)
13.1 Oncologic Emergencies I: Spinal Cord Compression, Hypercalcemia, Tamponade & SVC Syndrome 13.2 Oncologic Emergencies II: Hypersensitivity & Anaphylaxis, Sepsis, Pleural Effusion & Thromboembolism
15 Chapter 14: Professional Practice, Clinical Trials & Self-Care (Nursing Practice)
14.1 Professional Practice: Guidelines, Ethics, Legislation, Outreach & Accreditation 14.2 Clinical Trials in Breast Oncology 14.3 Nurse Self-Care: Compassion Fatigue, Burnout, Moral Distress & Substance Use
16 Chapter 15: Psychosocial Dimensions of Care (Psychosocial Dimensions)
15.1 Psychosocial Distress, Coping, Grief & Palliative Care 15.2 Culture, Spirituality, Sexual & Gender Identity, Age & Healthcare Disparities 15.3 Family & Caregiver Dynamics 15.4 Altered Body Image 15.5 Reproductive & Sexual Health
10.4 Trop-2 Antibody-Drug Conjugates, PI3K/AKT/mTOR Inhibitors & New Oral SERDs
Key Takeaways Explain This Topic AI
Sacituzumab govitecan is a Trop-2 antibody-drug conjugate with an SN-38 payload that improved survival in metastatic TNBC (ASCENT) and HR-positive, HER2-negative disease (TROPiCS-02) and carries boxed warnings for neutropenia and diarrhea.
The FDA approved datopotamab deruxtecan in January 2025 for previously treated HR-positive, HER2-negative metastatic breast cancer; stomatitis and ocular surface toxicity are its hallmark side effects.
Alpelisib, capivasertib, and inavolisib target the PI3K/AKT pathway in biomarker-selected HR-positive, HER2-negative advanced breast cancer, and hyperglycemia is their key shared toxicity.
Everolimus causes stomatitis that is reduced by prophylactic alcohol-free dexamethasone mouthwash, as shown in the SWISH trial.
The FDA approved the oral SERD imlunestrant in September 2025 for ER-positive, HER2-negative, ESR1-mutated advanced breast cancer after at least one endocrine therapy.
Last updated: September 2026
Why These Agents Matter
The CBCN outline lists systemic therapy broadly (endocrine therapy, chemotherapy, bispecific antibodies). Metastatic HR-positive and triple-negative breast cancer now move through a sequence that includes Trop-2 ADCs and PI3K-pathway inhibitors, each with toxicities that nurses must anticipate. Many of these drugs are oral, so patient education and adherence support are central.
Trop-2 Antibody-Drug Conjugates
Trop-2 (trophoblast cell-surface antigen 2) is expressed on most breast cancers regardless of subtype, so testing for Trop-2 is not required.
Sacituzumab Govitecan
Structure: anti-Trop-2 antibody linked to SN-38 , the active metabolite of irinotecan (a topoisomerase I inhibitor), with a hydrolyzable linker that allows a bystander effect.
Evidence: In ASCENT , for metastatic TNBC after at least two prior therapies (one for metastatic disease), median overall survival improved from 6.7 to 12.1 months versus chemotherapy. In TROPiCS-02 , it improved progression-free and overall survival in heavily pretreated HR-positive, HER2-negative metastatic disease.
Dosing: 10 mg/kg IV on days 1 and 8 of a 21-day cycle.
Boxed warnings: severe neutropenia and diarrhea . Hold for an absolute neutrophil count below 1,500 on day 1 (below 1,000 on day 8) or neutropenic fever; use G-CSF as secondary prophylaxis.
UGT1A1*28: patients homozygous for this allele clear SN-38 more slowly and have more neutropenia; monitor closely.
Diarrhea: early cholinergic diarrhea with cramping and sweating can be treated with atropine; later diarrhea is treated with loperamide after infection is excluded.
Other: hypersensitivity (premedicate with antipyretics and H1/H2 blockers), nausea (two- or three-drug antiemetic prophylaxis), alopecia, and fatigue.
Datopotamab Deruxtecan
Structure: anti-Trop-2 antibody with the same deruxtecan (topoisomerase I inhibitor) payload used in trastuzumab deruxtecan.
Evidence and approval: In TROPION-Breast01 , it improved progression-free survival versus chemotherapy in HR-positive, HER2-negative metastatic disease after endocrine therapy and one or two lines of chemotherapy. The FDA approved it on January 17, 2025.
Dosing: 6 mg/kg IV every 3 weeks.
Signature toxicities: stomatitis/oral mucositis (prophylactic steroid-containing mouthwash, such as dexamethasone swish-and-spit, plus oral care), ocular surface toxicity such as keratitis and dry eye (daily preservative-free lubricating drops, avoid contact lenses, ophthalmic exams), interstitial lung disease (same vigilance as trastuzumab deruxtecan), and nausea.
The PI3K/AKT/mTOR Pathway
The PI3K/AKT/mTOR pathway drives cell survival and growth and interacts with estrogen receptor signaling. About 40% of HR-positive, HER2-negative advanced breast cancers carry PIK3CA mutations; AKT1 mutations and PTEN loss add more. Testing uses next-generation sequencing of tumor tissue or circulating tumor DNA.
Drug Target Regimen and setting Key toxicities
Alpelisib PI3Kα With fulvestrant for PIK3CA -mutated HR+/HER2− advanced disease after endocrine therapy (SOLAR-1) Hyperglycemia, rash, diarrhea
Capivasertib AKT With fulvestrant for PIK3CA/AKT1/PTEN -altered disease after endocrine therapy (CAPItello-291; FDA November 2023); 400 mg twice daily, 4 days on and 3 days off Diarrhea, rash, hyperglycemia
Inavolisib PI3Kα With palbociclib and fulvestrant for endocrine-resistant PIK3CA -mutated disease that recurred on or within 12 months of adjuvant endocrine therapy (INAVO120; FDA October 2024) Hyperglycemia, stomatitis, diarrhea
Everolimus mTOR With exemestane after a nonsteroidal AI (BOLERO-2) Stomatitis, noninfectious pneumonitis, hyperglycemia, infections
Nursing Management
Hyperglycemia: check fasting glucose and HbA1c at baseline and optimize glucose control before starting; monitor glucose frequently in the first weeks (alpelisib hyperglycemia often begins within about 2 weeks). Metformin is the usual first-line agent; teach symptoms of hyperglycemia and ketoacidosis.
Rash: prophylactic non-sedating antihistamines reduce alpelisib rash; report blistering or mucosal involvement at once.
Stomatitis: the SWISH trial showed that alcohol-free dexamethasone mouthwash (swish 2 minutes, spit, four times daily) markedly reduced everolimus stomatitis; the same principle is used with other mTOR/PI3K agents.
Diarrhea: hydration, loperamide, and early reporting.
Pneumonitis: new cough or dyspnea on everolimus needs evaluation and possible dose hold.
New Oral SERDs and ESR1 Testing
ESR1 mutations arise under aromatase inhibitor pressure and make the estrogen receptor active without estrogen. Because they are acquired, retest by liquid biopsy at progression . Oral selective estrogen receptor degraders active against ESR1 -mutated disease include elacestrant (EMERALD) and imlunestrant , approved by the FDA on September 25, 2025, for ER-positive, HER2-negative, ESR1 -mutated advanced breast cancer after at least one endocrine therapy. Imlunestrant is taken as 400 mg once daily on an empty stomach, unlike elacestrant, which is taken with food. Teaching the correct food instruction for each oral agent is a practical nursing task.
Oral Anticancer Therapy Safety
Oral agents shift administration to the home. Nurses verify dose and schedule (including intermittent schedules such as capivasertib's 4 days on and 3 days off), review drug interactions (strong CYP3A4 inhibitors or inducers, grapefruit), teach safe handling and disposal, provide written toxicity action plans, and follow up by phone in the first weeks.
Putting the Agents in Sequence (HR-Positive, HER2-Negative Metastatic Disease)
A common pathway, individualized to biology and prior therapy:
First line: an aromatase inhibitor or fulvestrant plus a CDK4/6 inhibitor.
At progression: test tumor tissue or circulating tumor DNA for ESR1 , PIK3CA , AKT1 , and PTEN alterations, and confirm germline BRCA1/2 status.
Second-line endocrine-based options: an oral SERD (elacestrant or imlunestrant) for ESR1 mutations; capivasertib or alpelisib with fulvestrant for pathway alterations; inavolisib-based therapy for early relapse with a PIK3CA mutation; everolimus with exemestane; or a PARP inhibitor for germline BRCA carriers.
After endocrine resistance: antibody-drug conjugates (trastuzumab deruxtecan for HER2-low or HER2-ultralow disease, datopotamab deruxtecan, or sacituzumab govitecan) and single-agent chemotherapy.
Key Teaching Points for Patients
Bring a current medication list, including supplements, to every visit; many of these drugs interact through CYP3A4.
Report mouth sores early, before they limit eating.
Know your glucose targets and when to call if readings are high.
Keep a diarrhea log and start loperamide as instructed.
Report new cough, shortness of breath, or eye pain or blurred vision immediately.